Compare Eli Lilly And Co (LLY) vs Victoria's Secret & Co (VSXY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Victoria's Secret (VSXY) trades at $87.49, up 7.42% today, with a bullish technical signal and strong momentum. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 highlight improving fundamentals, while international growth and product innovation drive positive sentiment. The stock is near its consensus price target of $88.56, with net cash flow turning positive in 2026 projections.

Outlook remains favorable with analyst consensus at Buy (55.56% of coverage), though valuation multiples like P/E of 32.45 and net margin of 3.12% suggest premium pricing. Risks include competitive pressures and reliance on international expansion, but institutional support and earnings momentum support upside potential.